- Home
- OMER vs VBF Comparison
OMER vs VBF Comparison
Compare OMER & VBF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OMER
- VBF
- Stock Information
- Founded
- OMER 1994
- VBF 1970
- Country
- OMER United States
- VBF United States
- Employees
- OMER N/A
- VBF N/A
- Industry
- OMER Biotechnology: Pharmaceutical Preparations
- VBF Trusts Except Educational Religious and Charitable
- Sector
- OMER Health Care
- VBF Finance
- Exchange
- OMER Nasdaq
- VBF Nasdaq
- Market Cap
- OMER 188.1M
- VBF 176.7M
- IPO Year
- OMER 2009
- VBF N/A
- Fundamental
- Price
- OMER $3.65
- VBF $15.38
- Analyst Decision
- OMER Strong Buy
- VBF
- Analyst Count
- OMER 5
- VBF 0
- Target Price
- OMER $18.00
- VBF N/A
- AVG Volume (30 Days)
- OMER 936.6K
- VBF 45.5K
- Earning Date
- OMER 08-06-2025
- VBF 01-01-0001
- Dividend Yield
- OMER N/A
- VBF 5.18%
- EPS Growth
- OMER N/A
- VBF N/A
- EPS
- OMER N/A
- VBF N/A
- Revenue
- OMER N/A
- VBF N/A
- Revenue This Year
- OMER N/A
- VBF N/A
- Revenue Next Year
- OMER $468.75
- VBF N/A
- P/E Ratio
- OMER N/A
- VBF N/A
- Revenue Growth
- OMER N/A
- VBF N/A
- 52 Week Low
- OMER $2.95
- VBF $13.68
- 52 Week High
- OMER $13.60
- VBF $16.27
- Technical
- Relative Strength Index (RSI)
- OMER 54.74
- VBF 44.17
- Support Level
- OMER $3.00
- VBF $15.44
- Resistance Level
- OMER $3.25
- VBF $15.56
- Average True Range (ATR)
- OMER 0.24
- VBF 0.12
- MACD
- OMER 0.10
- VBF -0.01
- Stochastic Oscillator
- OMER 83.33
- VBF 20.59
About OMER Omeros Corporation
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
About VBF Invesco Bond Fund
Invesco Bond Fund is an independent investment management firm. Its investment objective is to seek interest income while conserving capital.